Presentations highlight company’s expertise seamlessly integrating human biology, data science and modern chemistry to advance a pipeline of investigational breakthrough precision oncology medicines
Cambridge, Mass., March 25, 2019 — H3 Biomedicine Inc., a U.S.-based precision medicine research & development subsidiary of Eisai Co., Ltd., today announced multiple presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting, being held March 29 through April 3, 2019 at the Georgia World Congress Center in Atlanta, GA.
Leveraging its integrated data science, human biology and precision chemistry discovery engine, H3 is advancing a pipeline of highly targeted, investigational breakthrough medicines to address critical unmet needs in the treatment of hematologic and solid tumor cancers. The company currently has three precision medicine therapeutic programs in clinical study with several additional research programs advancing toward the development stage.
H3’s presentations at this year’s AACR Annual Meeting showcase the company’s breadth of expertise in oncology research and the molecular insights enabled by its unique discovery engine.
The schedule for H3’s presentations is as follows (in chronological order):
Oral Presentation/Education Session:
Title:Targeting the spliceosome; perspectives from structural biology
Session:Chemistry to the Clinic: Part 2: Novel Chemical Tools and Leads for Unprecedented Targets
Date and Time: Saturday, March 30, 2019; 10:15 a.m. - 12:15 p.m. EDT
Location: Room A311-312
Presenter: Nicholas Larsen, Ph.D., Director, H3 Biomedicine
Abstract Number: 281
Title: Sensitivity to splicing modulation of BCL2 family genes reveals cancer therapeutic strategies for splicing modulators
Session: Combination Approaches to Novel Therapies
Date and Time: Sunday March 31, 2019; 1:00 p.m. - 5:00 p.m. EDT
Location: Exhibit Hall B; Poster Section 12; Poster Board Number 2
Title: Integrating bulk and spatial profiling technologies for the discovery of RNA and protein biomarkers in muscle invasive bladder cancer
Session: Imaging the Tumor Microenvironment
Date and Time: Sunday, March 31, 2019; 1:00 p.m. - 5:00 p.m. EDT
Location:Exhibit Hall B; Poster Section 20; Poster Board Number 11
Abstract Number: 2467
Title: Heme-CMap: Generation and characterization of ~20K L1000 profiles across 11 hematologic malignant lines
Session: Databases and Computational Tools for Cancer Discovery
Date and Time: Monday April 1, 2019; 1:00 p.m. - 5:00 p.m. EDT
Location: Exhibit Hall B; Poster Section 31; Poster Board Number 7
** In collaboration with the Broad Institute
About H3 Biomedicine
H3 Biomedicine, Inc. is a Cambridge, Massachusetts-based biopharmaceutical company specializing in the discovery and development of novel precision oncology treatments using its integrated data science, human biology and precision chemistry discovery engine with the goal of improving the lives of patients. The company was established in December 2010 as a subsidiary of Eisai’s U.S. pharmaceutical operation, Eisai Inc. H3 Biomedicine focuses on sustained long-term delivery of its pipeline, collaborating with Eisai Co., Ltd., who provides essential research funding and access to the capabilities and resources of a global pharmaceutical company. For more information, please visit www.h3biomedicine.com.